A B7-H3–targeted antibody-drug conjugate that binds B7-H3 on tumor cells, is internalized, and releases a deruxtecan topoisomerase I inhibitor payload to induce DNA damage and tumor cell death (with potential bystander effect).
Monoclonal antibody targets B7-H3 on tumor cells, undergoes internalization, and releases a deruxtecan topoisomerase I inhibitor payload that induces DNA damage and tumor cell death, with potential bystander killing.
YES
DIRECT
The ADC binds B7-H3 on target cells, is internalized, and releases a deruxtecan topoisomerase I inhibitor that induces DNA damage and apoptosis; the membrane-permeable payload can also cause bystander killing.
A B7-H3–targeted antibody-drug conjugate that binds B7-H3 on tumor cells, is internalized, and releases a deruxtecan topoisomerase I inhibitor payload to induce DNA damage and tumor cell death (with potential bystander effect).
Monoclonal antibody targets B7-H3 on tumor cells, undergoes internalization, and releases a deruxtecan topoisomerase I inhibitor payload that induces DNA damage and tumor cell death, with potential bystander killing.
NO
INDIRECT
I-DXd binds B7-H3 (not topoisomerase I), is internalized, and releases a deruxtecan topoisomerase I inhibitor that causes DNA damage. Cells are killed if they receive payload via B7-H3 targeting or bystander uptake; topoisomerase I is the intracellular enzymatic target, not the direct binding target.
Investigational subcutaneous anti-CD38 IgG1 monoclonal antibody expected to mirror daratumumab’s mechanisms (CDC, ADCC, ADCP, apoptosis via Fc cross-linking; depletion of CD38+ immunosuppressive cells).
Anti-CD38 IgG1 monoclonal antibody that binds CD38 on plasma/myeloma and other CD38+ cells, inducing complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), and triggering apoptosis via Fc cross-linking; also depletes CD38+ immunosuppressive cells to enhance antitumor immunity.
YES
DIRECT
Anti-CD38 IgG1 binds CD38 on target cells and induces complement-dependent cytotoxicity (CDC), NK cell–mediated ADCC, macrophage-mediated ADCP, and apoptosis via Fc cross-linking.
Subcutaneous anti-CD38 human IgG1κ monoclonal antibody (component of DARZALEX FASPRO) mediating CDC, ADCC, ADCP, and apoptosis; depletes CD38+ immunosuppressive cells.
Daratumumab is an anti‑CD38 human IgG1‑kappa monoclonal antibody that binds CD38 on malignant plasma cells and other CD38+ cells, inducing complement‑dependent cytotoxicity, antibody‑dependent cellular cytotoxicity, antibody‑dependent cellular phagocytosis, and apoptosis; it also depletes CD38+ immunosuppressive cells (e.g., Tregs, Bregs, MDSCs), enhancing anti‑tumor immunity.
YES
DIRECT
Anti-CD38 IgG1 binds CD38 on target cells and triggers complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity (NK cells via FcγR), antibody-dependent cellular phagocytosis (macrophages), and can induce apoptosis, killing CD38+ cells.
Humanized IgG1 monoclonal antibody targeting EGFR; blocks ligand binding and receptor activation, inhibiting downstream EGFR-RAS-RAF-MEK-ERK and PI3K-AKT signaling and may elicit ADCC against EGFR-expressing tumor cells.
Humanized IgG1 monoclonal antibody targeting EGFR; binds the extracellular domain to block ligand binding and receptor activation, inhibiting downstream RAS-RAF-MEK-ERK and PI3K-AKT signaling, which suppresses proliferation and survival of EGFR-expressing tumor cells, and may also elicit ADCC.
YES
DIRECT
IgG1 anti-EGFR antibody binds EGFR on tumor cells and recruits immune effectors via Fc–FcγR to mediate ADCC (and possibly CDC), killing EGFR+ cells; EGFR signaling blockade is antiproliferative.